Advanced search
Publication Cover
Acta Oncologica Volume 58, 2019 - Issue 6
Journal homepage
1,265
Views
2
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY

The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

Kirsi SanttiDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Correspondence[email protected]
View further author information
,
Annette BeuleDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; View further author information
,
Mikko RöntyDepartment of Pathology, HUSLAB and University of Helsinki, Helsinki, Finland; View further author information
,
Hanna IhalainenDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; ;Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; View further author information
,
Maija TarkkanenDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; View further author information
&
Carl BlomqvistDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; ;Department of Oncology, Örebro University Hospital, Örebro, SwedenView further author information
Pages 897-900 | Received 13 Jan 2019, Accepted 26 Feb 2019, Published online: 25 Mar 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure of interest

Ribociclib was provided by Novartis.

Acknowledgments

We want to thank Novartis for providing ribociclib for this study.

Additional information

Funding

This work was supported by the Helsinki University Hospital Research funds and Finska Läkaresällskapet.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report
Source: Figshare
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report
Source: Figshare

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.